- Home
- GFR vs CAPR Comparison
GFR vs CAPR Comparison
Compare GFR & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GFR
- CAPR
- Stock Information
- Founded
- GFR 2018
- CAPR 2005
- Country
- GFR Canada
- CAPR United States
- Employees
- GFR N/A
- CAPR N/A
- Industry
- GFR
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GFR
- CAPR Health Care
- Exchange
- GFR Nasdaq
- CAPR Nasdaq
- Market Cap
- GFR 321.0M
- CAPR 322.7M
- IPO Year
- GFR N/A
- CAPR N/A
- Fundamental
- Price
- GFR $4.56
- CAPR $7.96
- Analyst Decision
- GFR
- CAPR Strong Buy
- Analyst Count
- GFR 0
- CAPR 8
- Target Price
- GFR N/A
- CAPR $24.75
- AVG Volume (30 Days)
- GFR 21.4K
- CAPR 1.9M
- Earning Date
- GFR 08-06-2025
- CAPR 08-11-2025
- Dividend Yield
- GFR N/A
- CAPR N/A
- EPS Growth
- GFR N/A
- CAPR N/A
- EPS
- GFR 2.05
- CAPR N/A
- Revenue
- GFR $516,308,125.00
- CAPR $13,392,150.00
- Revenue This Year
- GFR $3.00
- CAPR $16.24
- Revenue Next Year
- GFR N/A
- CAPR $328.11
- P/E Ratio
- GFR $2.22
- CAPR N/A
- Revenue Growth
- GFR N/A
- CAPR N/A
- 52 Week Low
- GFR $3.81
- CAPR $3.84
- 52 Week High
- GFR $8.16
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- GFR 53.41
- CAPR 48.47
- Support Level
- GFR $4.27
- CAPR $7.60
- Resistance Level
- GFR $4.69
- CAPR $8.60
- Average True Range (ATR)
- GFR 0.19
- CAPR 0.64
- MACD
- GFR 0.00
- CAPR 0.15
- Stochastic Oscillator
- GFR 63.04
- CAPR 47.87
About GFR Greenfire Resources Ltd.
Greenfire Resources Ltd explores, acquires, develops and produces oil and gas in the Canadian energy sector and internationally. Greenfire currently has two producing oil sand assets, Hangingstone Expansion and Hangingstone Demo. The Company has one reportable operating segment which is made up of its oil sands operations based on geographic location : Athabasca oil sands region of Alberta, Canada, nature of the products sold and integration of facilities and operations.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.